Skip Header

Contribute Send feedback
Read comments (?) or add your own

Q15125 (EBP_HUMAN) Reviewed, UniProtKB/Swiss-Prot

Last modified January 25, 2012. Version 104. Feed History...

Clusters with 100%, 90%, 50% identity | Documents (6) | Third-party data text xml rdf/xml gff fasta
to top of pageNames·Attributes·General annotation·Ontologies·Sequence annotation·Sequences·References·Web links·Cross-refs·Entry info·DocumentsCustomize order

Names and origin

Protein namesRecommended name:
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase

EC=5.3.3.5
Alternative name(s):
Cholestenol Delta-isomerase
Delta(8)-Delta(7) sterol isomerase
Short name=D8-D7 sterol isomerase
Emopamil-binding protein
Gene names
Name:EBP
OrganismHomo sapiens (Human)
Taxonomic identifier9606 [NCBI]
Taxonomic lineageEukaryotaMetazoaChordataCraniataVertebrataEuteleostomiMammaliaEutheriaEuarchontogliresPrimatesHaplorrhiniCatarrhiniHominidaeHomo

Protein attributes

Sequence length230 AA.
Sequence statusComplete.
Sequence processingThe displayed sequence is further processed into a mature form.
Protein existenceEvidence at protein level

General annotation (Comments)

Function

Catalyzes the conversion of Delta(8)-sterols to their corresponding Delta(7)-isomers.

Catalytic activity

5-alpha-cholest-7-en-3-beta-ol = 5-alpha-cholest-8-en-3-beta-ol.

Pathway

Steroid biosynthesis; cholesterol biosynthesis.

Subcellular location

Endoplasmic reticulum membrane; Multi-pass membrane protein.

Involvement in disease

Defects in EBP are the cause of chondrodysplasia punctata X-linked dominant type 2 (CDPX2) [MIM:302960]; also known as Conradi-Hunermann-Happle syndrome. CDP is a clinically and genetically heterogeneous disorder characterized by punctiform calcification of the bones. The key clinical features of CDPX2 are chondrodysplasia punctata, linear ichthyosis, cataracts and short stature. CDPX2 is a rare disorder of defective cholesterol biosynthesis, biochemically characterized by an increased amount of 8-dehydrocholesterol and cholest-89-en-3-beta-ol in the plasma and tissues. Ref.8 Ref.9 Ref.10 Ref.11

Miscellaneous

Binds to the phenylalkylamine calcium-ion antagonist emopamil, an anti-ischemic drug.

Sequence similarities

Belongs to the EBP family.

Sequence annotation (Features)

Feature keyPosition(s)LengthDescriptionGraphical viewFeature identifier

Molecule processing

Initiator methionine11Removed By similarity
Chain2 – 2302293-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase
PRO_0000174342

Regions

Transmembrane29 – 4921Helical; Potential
Transmembrane66 – 8621Helical; Potential
Transmembrane121 – 14121Helical; Potential
Transmembrane185 – 20521Helical; Potential

Amino acid modifications

Modified residue21N-acetylthreonine By similarity

Natural variations

Natural variant801E → K in CDPX2. Ref.9
Corresponds to variant rs28936073 [ dbSNP | Ensembl ].
VAR_012105
Natural variant1101R → Q in CDPX2. Ref.8
VAR_012106
Natural variant1471R → G in CDPX2. Ref.11
VAR_012107
Natural variant1471R → H in CDPX2. Ref.9 Ref.10
Corresponds to variant rs28935174 [ dbSNP | Ensembl ].
VAR_012108

Experimental info

Mutagenesis681W → A: Reduces catalytic activity to less than 35% of wild-type.
Mutagenesis751I → A: Reduces catalytic activity to less than 35% of wild-type.
Mutagenesis761H → A: Reduces catalytic activity to less than 10% of wild-type.
Mutagenesis801E → A: Reduces catalytic activity to less than 10% of wild-type.
Mutagenesis1111Y → W: Reduces catalytic activity to less than 2% of wild-type. Ref.7
Mutagenesis1211M → A: Reduces catalytic activity to less than 35% of wild-type. Ref.7
Mutagenesis1211M → V: No effect on catalytic activity. Ref.7
Mutagenesis1221E → A: Reduces catalytic activity to less than 10% of wild-type.
Mutagenesis1251T → A: Reduces catalytic activity to less than 10% of wild-type.
Mutagenesis1881Y → A: Reduces catalytic activity to less than 35% of wild-type.
Mutagenesis1891F → A: Reduces catalytic activity to less than 35% of wild-type. Ref.7
Mutagenesis1891F → L: No effect on catalytic activity. Ref.7
Mutagenesis1931N → A: Reduces catalytic activity to less than 10% of wild-type.
Mutagenesis1961W → A: Reduces catalytic activity to less than 10% of wild-type.
Sequence conflict187 – 1882FY → IF in CAG33096. Ref.2

Sequences

Sequence LengthMass (Da)Tools
Q15125 [UniParc].

Last modified January 23, 2007. Version 3.
Checksum: 3931A9DE3DBAFA04

FASTA23026,353
        10         20         30         40         50         60 
MTTNAGPLHP YWPQHLRLDN FVPNDRPTWH ILAGLFSVTG VLVVTTWLLS GRAAVVPLGT 

        70         80         90        100        110        120 
WRRLSLCWFA VCGFIHLVIE GWFVLYYEDL LGDQAFLSQL WKEYAKGDSR YILGDNFTVC 

       130        140        150        160        170        180 
METITACLWG PLSLWVVIAF LRQHPLRFIL QLVVSVGQIY GDVLYFLTEH RDGFQHGELG 

       190        200        210        220        230 
HPLYFWFYFV FMNALWLVLP GVLVLDAVKH LTHAQSTLDA KATKAKSKKN 

« Hide

References

« Hide 'large scale' references
[1]"Phenylalkylamine Ca2+ antagonist binding protein. Molecular cloning, tissue distribution, and heterologous expression."
Hanner M., Moebius F.F., Weber F., Grabner M., Striessnig J., Glossmann H.
J. Biol. Chem. 270:7551-7557(1995) [PubMed: 7706302] [Abstract]
Cited for: NUCLEOTIDE SEQUENCE [MRNA].
Tissue: Liver.
[2]"Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201)."
Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.
Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
[3]"The DNA sequence of the human X chromosome."
Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D., Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C. expand/collapse author list , Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S., Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S., Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D., Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H., McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K., Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D., Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R., Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A., Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F., Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S., Rogers J., Bentley D.R.
Nature 434:325-337(2005) [PubMed: 15772651] [Abstract]
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
[4]Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., Turner R. expand/collapse author list , Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W., Venter J.C.
Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
[5]"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."
The MGC Project Team
Genome Res. 14:2121-2127(2004) [PubMed: 15489334] [Abstract]
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
Tissue: Cervix and Placenta.
[6]"Histidine77, glutamic acid81, glutamic acid123, threonine126, asparagine194, and tryptophan197 of the human emopamil binding protein are required for in vivo sterol delta 8-delta 7 isomerization."
Moebius F.F., Soellner K.E.M., Fiechtner B., Huck C.W., Bonn G., Glossmann H.
Biochemistry 38:1119-1127(1999) [PubMed: 9894009] [Abstract]
Cited for: MUTAGENESIS.
[7]"Cloning of an emopamil-binding protein (EBP)-like protein that lacks sterol delta8-delta7 isomerase activity."
Moebius F.F., Fitzky B.U., Wietzorrek G., Haidekker A., Eder A., Glossmann H.
Biochem. J. 374:229-237(2003) [PubMed: 12760743] [Abstract]
Cited for: MUTAGENESIS OF TYR-111; MET-121 AND PHE-189.
[8]"Mutations in a delta(8)-delta(7) sterol isomerase in the tattered mouse and X-linked dominant chondrodysplasia punctata."
Derry J.M.J., Gormally E., Means G.D., Zhao W., Meindl A., Kelley R.I., Boyd Y., Herman G.E.
Nat. Genet. 22:286-290(1999) [PubMed: 10391218] [Abstract]
Cited for: VARIANT CDPX2 GLN-110.
[9]"Mutations in the gene encoding 3-beta-hydroxysteroid-delta(8),delta(7)-isomerase cause X-linked dominant Conradi-Hunermann syndrome."
Braverman N., Lin P., Moebius F.F., Obie C., Moser A., Glossmann H., Wilcox W.R., Rimoin D.L., Smith M., Kratz L., Kelley R.I., Valle D.
Nat. Genet. 22:291-294(1999) [PubMed: 10391219] [Abstract]
Cited for: VARIANTS CDPX2 LYS-80 AND HIS-147.
[10]"The Conradi-Hunermann-Happle syndrome (CDPX2) and emopamil binding protein: novel mutations, and somatic and gonadal mosaicism."
Has C., Bruckner-Tuderman L., Muller D., Floeth M., Folkers E., Donnai D., Traupe H.
Hum. Mol. Genet. 9:1951-1955(2000) [PubMed: 10942423] [Abstract]
Cited for: VARIANT CDPX2 HIS-147.
[11]"Identification of a novel mutation in 3beta-hydroxysteroid-Delta8-Delta7-isomerase in a case of Conradi-Hunermann-Happle syndrome."
Becker K., Csikos M., Horvath A., Karpati S.
Exp. Dermatol. 10:286-289(2001) [PubMed: 11493318] [Abstract]
Cited for: VARIANT CDPX2 GLY-147.
+Additional computationally mapped references.

Web resources

Cross-references

Sequence databases

EMBL
GenBank
DDBJ
Z37986 mRNA. Translation: CAA86068.1.
CR456815 mRNA. Translation: CAG33096.1.
CR542094 mRNA. Translation: CAG46891.1.
AF196969 Genomic DNA. No translation available.
AF196972 Genomic DNA. No translation available.
CH471224 Genomic DNA. Translation: EAW50773.1.
BC001549 mRNA. Translation: AAH01549.1.
BC001572 mRNA. Translation: AAH01572.1.
BC046501 mRNA. Translation: AAH46501.1.
IPIIPI00008599.
PIRB56122.
RefSeqNP_006570.1. NM_006579.2.
UniGeneHs.30619.

3D structure databases

ProteinModelPortalQ15125.
ModBaseSearch...

Protein-protein interaction databases

IntActQ15125. 1 interaction.
STRINGQ15125.

Polymorphism databases

DMDM17374795.

Proteomic databases

PeptideAtlasQ15125.
PRIDEQ15125.

Protocols and materials databases

StructuralBiologyKnowledgebaseSearch...

Genome annotation databases

EnsemblENST00000495186; ENSP00000417052; ENSG00000147155.
GeneID10682.
KEGGhsa:10682.
UCSCuc004djx.2. human.

Organism-specific databases

CTD10682.
GeneCardsGC0XP048380.
H-InvDBHIX0203294.
HGNCHGNC:3133. EBP.
HPAHPA003130.
MIM300205. gene.
302960. phenotype.
neXtProtNX_Q15125.
Orphanet35173. X-linked dominant chondrodysplasia punctata.
PharmGKBPA27587.
GenAtlasSearch...

Phylogenomic databases

eggNOGprNOG10454.
GeneTreeENSGT00530000063715.
HOGENOMHBG590959.
HOVERGENHBG018176.
InParanoidQ15125.
OMAPTWHILA.
OrthoDBEOG45490D.
PhylomeDBQ15125.

Enzyme and pathway databases

BioCycMetaCyc:ENSG00000147155-MONOMER.
BRENDA5.3.3.5. 2681.
ReactomeREACT_22258. Metabolism of lipids and lipoproteins.

Gene expression databases

ArrayExpressQ15125.
BgeeQ15125.
CleanExHS_EBP.
GenevestigatorQ15125.
GermOnlineENSG00000147155. Homo sapiens.

Family and domain databases

InterProIPR007905. EBP.
[Graphical view]
KOK01824.
PANTHERPTHR14207. EBP. 1 hit.
PfamPF05241. EBP. 1 hit.
[Graphical view]
ProtoNetSearch...

Other

NextBio40611.
SOURCESearch...

Entry information

Entry nameEBP_HUMAN
AccessionPrimary (citable) accession number: Q15125
Secondary accession number(s): Q6FGL3, Q6IBI9
Entry history
Integrated into UniProtKB/Swiss-Prot: October 18, 2001
Last sequence update: January 23, 2007
Last modified: January 25, 2012
This is version 104 of the entry and version 3 of the sequence. [Complete history]
Entry statusReviewed (UniProtKB/Swiss-Prot)
Annotation programChordata Protein Annotation Program
DisclaimerAny medical or genetic information present in this entry is provided for research, educational and informational purposes only. It is not in any way intended to be used as a substitute for professional medical advice, diagnosis, treatment or care.

Relevant documents

Human chromosome X

Human chromosome X: entries, gene names and cross-references to MIM

Human entries with polymorphisms or disease mutations

List of human entries with polymorphisms or disease mutations

Human polymorphisms and disease mutations

Index of human polymorphisms and disease mutations

MIM cross-references

Online Mendelian Inheritance in Man (MIM) cross-references in UniProtKB/Swiss-Prot

PATHWAY comments

Index of metabolic and biosynthesis pathways

SIMILARITY comments

Index of protein domains and families